Pharmaceutical company Shield Therapeutics has experienced a significant boost in revenues and a narrowing of losses, primarily driven by the success of its iron deficiency-fighting tablets in the United States. The company, known for its product Accrufer in most territories and Ferracru in Europe, has witnessed a substantial increase in group revenues, prescription sales, and average net selling price. In the first half of 2025, Shield Therapeutics reported a rise in group revenues from $12.1 million to $21.4 million, with Accrufer revenue climbing from $11 million to $19.2 million.
The surge in revenues was fueled by approximately 84,000 prescriptions, mainly concentrated in six major states in the US, including Texas, New York, and California. Shield Therapeutics also noted a significant increase in milestones and royalties from global partners in regions such as Europe, Canada, and Japan. The company’s losses decreased from $15.5 million to $9.5 million, a result of higher Accrufer revenues and strategic cost-cutting measures implemented within the organization.
Shield Therapeutics attributed its positive financial performance to key strategic initiatives, such as restructuring its consignment business, revamping the sales force, and leveraging digital marketing campaigns. The company highlighted its successful partnerships in Canada, Japan, and China, emphasizing its commitment to collaborating with a growing network of global partners to expand the availability of its products worldwide. Shield Therapeutics’ recent exclusive license agreement with Vital-Net to enter the Japanese market signifies its strategic expansion into one of the world’s largest pharmaceutical markets.
Anders Lundstrom, CEO of Shield Therapeutics, expressed optimism about Accrufer’s robust performance and the increasing market adoption of the product, underscoring its substantial potential in addressing unmet needs in the oral iron therapy market. The company’s focus on driving sustained growth and establishing Accrufer as a preferred treatment for iron deficiency reflects its dedication to meeting patient needs globally. With a strengthened cash position and a projected path to positive cash flow by the end of 2025, Shield Therapeutics remains committed to its growth trajectory and expanding access to patients worldwide.
In conclusion, Shield Therapeutics’ success in boosting revenues and reducing losses underscores the impact of its iron deficiency-fighting tablets, particularly in the lucrative US market. The company’s strategic initiatives, strong partnerships, and commitment to innovation position it for continued growth and market expansion. As Shield Therapeutics navigates the evolving pharmaceutical landscape, its focus on addressing unmet medical needs and driving commercial success sets a promising trajectory for the future.
- Shield Therapeutics reports a significant increase in group revenues and Accrufer sales, driven by successful penetration of the US market.
- Strategic initiatives, including restructuring efforts and digital marketing campaigns, contribute to the company’s improved financial performance.
- Partnerships with global entities in Canada, Japan, and China demonstrate Shield Therapeutics’ commitment to expanding its product reach internationally.
- With a focus on driving sustained growth and establishing Accrufer as a preferred treatment for iron deficiency, the company remains on track to achieve positive cash flow by the end of 2025.
Tags: regulatory
Read more on business-live.co.uk